Efficacy and Safety of Paritaprevir/Ritonavir, Ombitasvir and Dasabuvir Plus/Minus Ribavirin for Treatment of HCV Genotype 1B Compensated Cirrhosis in Patients Aged 70 Years or Older

GASTROENTEROLOGY(2017)

引用 13|浏览36
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要